Last reviewed · How we verify

SPM 927 — Competitive Intelligence Brief

SPM 927 (SPM 927) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: T-type calcium channel blocker. Area: Neurology.

phase 3 T-type calcium channel blocker T-type calcium channel (Cav3.1, Cav3.2, Cav3.3) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

SPM 927 (SPM 927) — UCB Pharma. SPM 927 is a selective T-type calcium channel blocker that reduces neuronal excitability and seizure activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SPM 927 TARGET SPM 927 UCB Pharma phase 3 T-type calcium channel blocker T-type calcium channel (Cav3.1, Cav3.2, Cav3.3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (T-type calcium channel blocker class)

  1. UCB Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SPM 927 — Competitive Intelligence Brief. https://druglandscape.com/ci/spm-927. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: